



# European Dermatology Forum

## Guideline on the diagnosis and treatment of dermatofibrosarcoma protuberans

Developed by the Guideline Subcommittee of the  
**European Dermatology Forum**

### *Subcommittee Members:*

Prof. Dr. Philippe Saiag, Boulogne (France)  
Prof. Dr. Celeste Lebbe, Paris (France)  
Dr. Veronique del Marmol, Brussels (Belgium)  
Prof. Dr. Ketty Peris, Rome (Italy)  
Prof. Dr. Mark Middleton, Oxford (United Kingdom)  
Dr. Alessandro Testori, Milano (Italy)

Prof. Dr. Jean-Jacques Grob, Marseille (France)  
Dr. Josep Malvehy, Barcelona (Spain)  
Prof. Dr. Hubert Pehamberger, Vienna (Austria)  
Prof. Dr. Alexander Stratigos, Athens (Greece)  
Dr. Lars Bastholt, Odense (Denmark)  
Prof. Dr. Claus Garbe, Tübingen (Germany)

### *Members of EDF Guideline Committee:*

Prof. Dr. Werner Aberer, Graz (Austria)  
Prof. Dr. Martine Bagot, Paris (France)  
Prof. Dr. Nicole Basset-Seguin, Paris (France)  
Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany)  
Prof. Dr. Lasse Braathen, Bern (Switzerland)  
Prof. Dr. Sergio Chimenti, Rome (Italy)  
Prof. Dr. Alexander Enk, Heidelberg (Germany)  
Prof. Dr. Claudio Feliciani, Rome (Italy)  
Prof. Dr. Claus Garbe, Tuebingen (Germany)  
Prof. Dr. Harald Gollnick, Magdeburg (Germany)  
Prof. Dr. Gerd Gross, Rostock (Germany)  
Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia)  
Prof. Dr. Michael Hertl, Marburg (Germany)  
Prof. Dr. Dimitrios Ioannides, Thessaloniki (Greece)  
Prof. Dr. Gregor Jemec, Roskilde (Denmark)  
Prof. Dr. Lajos Kemény, Szeged (Hungary)  
Dr. med. habil. Gudula Kirtschig, Nottingham (United Kingdom)  
Prof. Dr. Elke Weisshaar, Heidelberg (Germany)  
Prof. Dr. Sean Whittaker, London (United Kingdom)  
Prof. Dr. Fenella Wojnarowska, Oxford (United Kingdom)  
Prof. Dr. Marcus Maurer, Berlin (Germany)  
Prof. Dr. Kai Munte, Rotterdam (Netherlands)

Prof. Dr. Dieter Metze, Muenster (Germany)  
Prof. Dr. Gillian Murphy, Dublin (Ireland)  
PD Dr. Alexander Nast, Berlin (Germany)  
Prof. Dr. Martino Neumann, Rotterdam (Netherlands)  
Prof. Dr. Tony Ormerod, Aberdeen (United Kingdom)  
Prof. Dr. Mauro Picardo, Rome (Italy)  
Prof. Dr. Annamari Ranki, Helsinki (Finland)  
Prof. Dr. Johannes Ring, Munich (Germany)  
Prof. Dr. Berthold Rzany, Berlin (Germany)  
Prof. Dr. Rudolf Stadler, Minden (Germany)  
Prof. Dr. Sonja Ständer, Muenster (Germany)  
Prof. Dr. Wolfram Sterry, Berlin (Germany)  
Prof. Dr. Eggert Stockfleth, Berlin (Germany)  
Prof. Dr. Alain Taieb, Bordeaux (France)  
Prof. Dr. George-Sorin Tîplica, Bucharest (Romania)  
Prof. Dr. Nikolai Tsankov, Sofia (Bulgaria)  
Prof. Dr. Robert Knobler, Vienna (Austria)  
Prof. Dr. Annegret Kuhn, Muenster (Germany)  
Prof. Dr. Christos Zouboulis, Dessau (Germany)  
Prof. Dr. Torsten Zuberbier, Berlin (Germany)

### *Chairman of EDF Guideline Committee:*

PD Dr. Alexander Nast, Berlin (Germany)

Expiry date: 09/2017

---

*EDF Guidelines Secretariat to PD Dr. Alexander Nast:*

Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte,  
Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany  
phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: [bettina.schulze@charite.de](mailto:bettina.schulze@charite.de)

## Conflicts of interests – Lars Bastholt

The Work Under Consideration for Publication					
		Astra Zeneca	BMS	Roche	Merck
1	Grant	no	no	no	no
2	Consulting fee or honorarium	no	no	no	no
3	Support for travel to meetings for the study or other purposes	no	no	no	no
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	no	no	no	no
5	Payment for writing or reviewing the manuscript	no	no	no	no
6	Provision of writing assistance, medicines, equipment, or administrative support	no	no	no	no
7	Other	no	no	no	no

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	no	no	no	no
2	Consultancy	Yes	Yes	Yes	Yes
3	Employment	no	no	no	no
4	Expert testimony	no	no	no	no
5	Grants/grants pending	no	no	no	no
6	Payment for lectures including service on speakers bureaus	no	no	no	no
7	Payment for manuscript preparation	no	no	no	no
8	Patents (planned, pending or issued)	no	no	no	no
9	Royalties	no	no	no	no
10	Payment for development of educational presentations	no	no	no	no
11	Stock/stock options	no	no	no	no
12	Travel/accommodations/meeting expenses unrelated to activities listed**	Yes	Yes	Yes	Yes
13	Other (err on the side of full disclosure)	no	no	no	no

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships				
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	no	no	no

## Conflicts of interests – Claus Garbe

The Work Under Consideration for Publication					
		Name	Name	Name	Name
1	Grant	no			
2	Consulting fee or honorarium	no			
3	Support for travel to meetings for the study or other purposes	no			
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	no			
5	Payment for writing or reviewing the manuscript	no			
6	Provision of writing assistance, medicines, equipment, or administrative support	no			
7	Other	no			

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	Amgen	BMS, GSK	MSD; Novartis	Roche
2	Consultancy	Amgen	BMS, GSK	MSD, Novartis	Roche
3	Employment	no			
4	Expert testimony	no			
5	Grants/grants pending	BMS	GSK	Roche	
6	Payment for lectures including service on speakers bureaus	Amgen	BMS, GSK	MSD, Novartis	Roche
7	Payment for manuscript preparation	no			
8	Patents (planned, pending or issued)	no			
9	Royalties	no			
10	Payment for development of educational presentations	no			
11	Stock/stock options	no			
12	Travel/accommodations/meeting expenses unrelated to activities listed**	BMS	Roche		
13	Other (err on the side of full disclosure)	no			

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships					
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	no			



## Conflicts of interests

Jean Jacques Grol

The Work Under Consideration for Publication					
		Name	Name	Name	Name
1	Grant	0			
2	Consulting fee or honorarium	0			
3	Support for travel to meetings for the study or other purposes	0			
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	0			
5	Payment for writing or reviewing the manuscript	0			
6	Provision of writing assistance, medicines, equipment, or administrative support	0			
7	Other				

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	Meda, Leo, galderma, almirall	Unrelated to SCC GSK, Roche, BMS, Merck, celgene,		
2	Consultancy	0			
3	Employment	0			
4	Expert testimony	0			
5	Grants/grants pending	0			
6	Payment for lectures including service on speakers bureaus	0			
7	Payment for manuscript preparation	0			
8	Patents (planned, pending or issued)	0			
9	Royalties	0			
10	Payment for development of educational presentations	Linked to SCC/KA Almirall	Unrelated to SCC GSK, Roche, BMS		
11	Stock/stock options	0			
12	Travel/accommodations/meeting expenses unrelated	0	Unrelated to SCC GSK, Roche,		

	to activities listed**				
13	Other (err on the side of full disclosure)	Institutional funding from approx.. 20 pharma companies (fee for service for commercial clinical trials)			

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships					
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	No			

## Conflicts of interests Celeste Lebbe

The Work Under Consideration for Publication					
		Name	Name	Name	Name
1	Grant				
2	Consulting fee or honorarium				
3	Support for travel to meetings for the study or other purposes				
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like				
5	Payment for writing or reviewing the manuscript				
6	Provision of writing assistance, medicines, equipment, or administrative support				
7	Other				

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	BMS	MSD	ROCHE	Novartis, GSK Amgen
2	Consultancy			Roche	GSK
3	Employment				
4	Expert testimony				
5	Grants/grants pending				
6	Payment for lectures including service on speakers bureaus				
7	Payment for manuscript preparation				
8	Patents (planned, pending or issued)				
9	Royalties				
10	Payment for development of educational presentations				
11	Stock/stock options				
12	Travel/accommodations/meeting expenses unrelated to activities listed**			Support to go to the ASCO and ESMO meeting in 2014	
13	Other (err on the side of full)				